Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 Preview: Post-2012 Message a Growing Focus: WPI and IPXL Top Ideas
Tweet
Share
E-mailGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Rating Summary:
13 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 33
Join SI Premium – FREE
Canaccord Genuity on Life Sciences/Specialty Pharmaceuticals: Q4/11 preview: post-2012 message a growing focus; WPI and IPXL top ideas
Analyst, Randall Stanicky, said, "Calendar Q4 earnings will be a non-event for most – but other catalysts exists With half of our coverage already pre-announcing or providing 2012 guidance, we believe Q4 results will be a non-event for several of our companies. Relative to themes, there are three things to focus on from the calls: (1) the message around growth in 2013 and beyond; (2) color around non-earnings related catalysts (we see several); and (3) M&A discussion as we expect more deal activity with a “buy the buyer” set-up. Our top ideas remain Watson (NYSE: WPI) (mid/large cap) and Impax Laboratories (Nasdaq: IPXL) (small cap) – both are rated BUY and fit well into the themes above."
"Q4 updates key for Perrigo (Nasdaq: PRGO) and Mylan (NYSE: MYL) (both HOLD); WPI and IPXL (both BUY) still top ideas Post a bottom-up review of our coverage, we think most Q4 volatility will come from MYL and PRGO but for different reasons – they are also the only two (> $1 billion in cap) to not have either pre-announced or given a guidance update. Our two top BUY ideas remain WPI and IPXL but we frankly see little surprise coming from either with Q4 earnings."
Analyst, Randall Stanicky, said, "Calendar Q4 earnings will be a non-event for most – but other catalysts exists With half of our coverage already pre-announcing or providing 2012 guidance, we believe Q4 results will be a non-event for several of our companies. Relative to themes, there are three things to focus on from the calls: (1) the message around growth in 2013 and beyond; (2) color around non-earnings related catalysts (we see several); and (3) M&A discussion as we expect more deal activity with a “buy the buyer” set-up. Our top ideas remain Watson (NYSE: WPI) (mid/large cap) and Impax Laboratories (Nasdaq: IPXL) (small cap) – both are rated BUY and fit well into the themes above."
"Q4 updates key for Perrigo (Nasdaq: PRGO) and Mylan (NYSE: MYL) (both HOLD); WPI and IPXL (both BUY) still top ideas Post a bottom-up review of our coverage, we think most Q4 volatility will come from MYL and PRGO but for different reasons – they are also the only two (> $1 billion in cap) to not have either pre-announced or given a guidance update. Our two top BUY ideas remain WPI and IPXL but we frankly see little surprise coming from either with Q4 earnings."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades Robinhood, sees 43% upside
- Morgan Stanley Upgrades Mitsubishi Chemical Holdings (4188:JP) (MTLHY) to Overweight
- Medtronic jumps on earnings beat and raised guidance
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
